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A delicate balance exists between the gastrointestinal 
microbiota and its host animal. It is a symbiotic 
relationship that has evolved with the host and is 
essential for optimal health. In the wild state, the 
equilibrium which is established is seldom threatened. 
However, under domestic conditions such as those 
which exist in the human environment, there are several 
factors, such as diet, medication and stress, which can 
influence the composition and/or activity of the gut 
flora-this may often be to the detriment of the host. 
At birth, the human intestinal tract is sterile, but it 
rapidly acquires microorganisms from the mother, 
other external contacts and the general environment. 
In developed countries, the baby is born into an 
environment in which hygiene has a high priority. 
Consequently, transfer of microorganisms from the 
mother to offspring may be compromised and the baby 
could be colonized by inappropriate species of micro- 
organism, such that the characteristic gut flora of the 
human infant does not fully develop. This is seen in its 
most extreme form when babies delivered by Caesarean 
section are transferred to isolators. In these cases, 
development of the lactobacillus flora is delayed [l]. In 
.I sense, the environment is too clean, but the possibility 
of transfer of pathogens means that the standards of 
hygiene cannot be relaxed. Instead, restoration of the 
gut microflora may be tackled by selectively introduc- 
ing certain components involved in protection against 
infection. This has been achieved either by administer- 
ing live microorganisms (probiotics) or by dosing with 
chemicals which stimulate the growth and metabolism 
of bacteria in the lower gut (prebiotics). The formal 
definitions of these two approaches are as follows: 
1. 
2 .  
Probiotics are live microbial feed supplements which 
beneficially affect the host animal by improving its 
intestinal microbial balance [2]. 
Prebiotics are non-digestible food ingredients that 
beneficially affect the host by stimulating the growth 
and/or activity of one or a limited number ofbacteria 
in the colon that can improve host health [3]. 
Both approaches operate by increasing the number of 
lactic acid bacteria (e.g. lactobacilli, streptococci, enter- 
ococci and bifidobacteria). These groups are normal 
inhabitants of the gut and have been used in health 
foods for many years without any adverse effects. 
Prebiotics target specific bacteria already in the colon. 
Yeasts (Saccharomyces cerevisiae and Saccharomyces boulardiq 
and certain species of Bacillus have also been developed 
as probiotics. Products for human consumption, which 
exploit both approaches, may have profound effects on 
certain target groups where the gut flora composition 
may be compromised. These include infants, the elderly 
and hospitalized patients. However, it is clear that their 
development is not directed towards a niche market, 
but is suitable for the wider approach. 
Probiotics 
The probiotic approach uses live microorganisms to 
enhance the microbial population of the lower gut. The 
minimum effective dose is not precisely known, but 
numbers in excess of lo9 CFU/per day are usually 
recommended. Whether multiplication and coloniza- 
tion of the gut are essential is questionable, because 
organisms like the yogurt starters (Lactobacillus delbreuckii 
subsp. bnlgaricns and Streptococcus salit~arius subsp. thermo- 
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pliilirs), which are often included in probiotic prepara- 
tions, are not gut colonizers. There is, however, a 
requirement for survival and active metabolism in 
order for probiotic effects to be manifested. Therefore, 
attention to colonization factors such as ability to 
adhere to the gut epithelial sudace may be important 
to maximize residence time in the gut. Moreover, the 
most efficacious strains will have enhanced oxygen, pH 
and bile tolerance. 
Although this paper will deal only with the effects 
that probiotic preparations have on resistance to 
intestinal infections, it should be noted that claims have 
also been made for their efficacy in other areas, such as 
vaginitis, lactose malabsorption, urinary tract infec- 
tions, cancer and coronary heart disease [4,5]. 
A great deal of information has accumulated from 
anecdotal reports and results generated by poorly 
designed and inadequately analyzed experiments and 
clinical trials. However, there are good examples of 
positive results gained from carefully conducted trials 
in humans, e.g. those using double-blind, placebo- 
controlled, crossover techniques. One  of the most 
important, and best-documented, areas is that of 
antibiotic-associated diarrhea (AAD). Clortridirrm d@iile 
is recognized as the causative agent of pseudomeni- 
branous colitis, which often follows administration of 
antibiotics, especially broad-spectrum preparations. The 
condition can be difficult to resolve by conventional 
means. Yeast probiotics have given encouraging results. 
In two well-controlled trials, a large number of patients 
were treated with Saciharornycer houlardii. This treatment 
resulted in a significant reduction in the number of 
patients developing AAD [h,7]. The mechanism of 
effect is still not known but it has been suggested that 
the yeast may be moderating the effects of Clostridicrm 
difficilc by degrading receptors on the gut wall specific 
for cell adhesion or toxin binding [8] .  
Overgrowth of C a ~ d i d a  in the gut is also a frequent 
consequence of antibiotic therapy. Studies in hamsters 
have shown that the gut microflora is involved in 
suppression of C m d i d a  albicarzs [9]. In gnotobiotic mice, 
Sarc l iavorqm~ houlardii protected against colonization of 
the gut by Carididu albicanr [lo]. One human trial 
in patients undergoing chemotherapy treatment for 
leukemia showed that a milk preparation containing 
L. nridoyhiliir and 3 B~fidobnrferirim species was effective 
in reducing the count of CaMdidn in feces [ I  11. 
There is also evidence that Larrobacillris GG can 
influence the course of diarrhea in children. In a well- 
controlled trial it was rhown that adniiiiistration of this 
probiotic could reduze the duration of diarrhea in 
children aged 4-45 months. The results were most 
pronounced when the data were related to those 
patients with confirmed rotavirus infection [12]. 
For probiotics containing bifidobacteria, there have 
been encouraging results against AAD [13,14]. Clostvid- 
ium dtjicile [ 151 and childhood forms of diarrhea [ 16,171. 
There is therefore evidence for activity of pro- 
biotics against a wide range of intestinal pathogens. 
Despite this, the mechanisms of effect have been poorly 
defined. However, it can be speculated that one or 
more of the following possible effects are in operation: 
0 conipetition for nutrients; 
secretion of antimicrobial substances (e.g. bacterio- 
0 reduction of gut pH; 
0 blocking of adhesion sites; 
0 repression of virulence; 
0 blocking of toxin receptor sites; 
0 iinmurie stimulation (local and cystemic); 
suppression of toxin production. 
cins, peroxides); 
Probiotics is a generic term that covers a wide 
variety of different products comprising tablets, powders, 
fermented milks (bioyogurts) and liquid suspensions. 
They may contain from one species of microorganism 
(e.g. Yakult) to as many as seven (e.g. Protexin). It is, 
therefore, difficult to summarize all the variable effects 
that have been reported. Not all trials give positive 
results; there are many good reaconc for this variation, 
not the least being the low viable counts of some 
preparations 151. However, there are many reliable trials 
which confirm the activity of probiotic preparations 
and show that gut microflora modulation has the 
potential to generate significant effects on the health of 
the consumer. 
Prebiotics 
The concept of selected microflora modulation by diet 
is not a new one. However, the term ‘prebiotic’ was 
first coined in 1995 to describe dietary components 
that could influence the composition of the human 
large gut such that probiotic microorganisms, such as 
bifidobacteria, could predominate [3]. In operation, 
prebiotics therefore act like dietary fiber-type carbo- 
hydrates in that they enter the colon in an intact form 
and are fermented by the large gut flora. However, as 
prebiotics require a selective type of metabolism. they 
act in a much more specific manner than fibers. 
Most present attention is directed towards oligo- 
5accharides, particularly those which contain fructose. 
A number of huiiiari volunteer trials have demonstrated 
that fructo-oligosaccharides (FOS) are very adept at  
stimulating bifidobacterial growth in the large intestine 
1e.g. 18-20]. While the definitive health consequences 
of prebiotic intake remain to be defined, there is much 
current interest in influences on pathogenic bacteria, 
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bowel cancer, cholesterol levels, mineral absorption and 
gut immune function. In essence, therefore, the targeted 
health benefits are similar to those of probiotics. Both 
‘ipproaches aim to enhance the activities of ‘health- 
promoting’ bacteria. 
In terms of product range, it is probable that 
prebiotics have the wider role. As they exploit non- 
viable food ingredients, survivability in the product and 
.&er ingestion is not a major issue. Moreover, prebiotics 
should not be affected by heat treatment. In particular, 
dairy products, infant formula feeds, cereals, weaning 
foods, drinks, confectionery and biscuits would be 
appropriate vehicles for use. However, it is important 
that the minimum dose required be determined. In this 
respect, it would appear that 4 g/day of FOS exerts a 
reasonable prebiotic effect. It would be very difficult to 
attain this level of intake through the consumption of 
foodstuffs that have a high FOS content (e.g. onions, 
asparagus, chicory, artichoke, banana). A more feasible 
route, therefore, appears to be the deliberate incor- 
poration of FOS, and related compounds, into products 
such as those mentioned above. 
Most research on bifidogenic prebiotics has 
involved FOS and, to a lesser degree, galacto- 
oligosaccharides (GOS) [21], whilst lactulose has also 
aroused interest as a good stimulator of lactobacilli in 
the gut [22]. However, it is almost certain that other 
prebiotics exist. For example, mannose-, maltose-, 
.uylose- and gluco-oligosaccharides have not been well 
researched. Moreover, advances in enzyme technology 
offer the potential for manufacture of ‘designer’ 
prebiotics. In some cases, these may have certain 
advantages over the current market leaders. Some 
examples of how this may be achieved are as follows: 
0 lower dosage effects than FOS/GOS; 
0 enhanced sensory properties; 
0 more than one biological activity (e.g. prebiotic as 
0 stimulate both bifidobacteria and lactobacilli; 
0 clear repressive effects on known pathogens; 
0 good viscosity regulation; 
0 ability to attenuate virulence in pathogens as well as 
0 gastrointestinal, as well as systemic, effects; 
0 ease of incorporation into common foodstuffs. 
The future search for efficacious probiotics and 
prebiotics should exploit the latest techniques available 
to bacteriologists and nutritionists. In this case, a 
molecular approach to gut microbiology is indispen- 
sible. It  is important that microflora changes in response 
to dietary intervention are tracked with precision and 
reliability. Here genetic fingerprinting, probe develop- 
ment, molecular marking and gene-sequencing pro- 
well as anti-adhesive); 
act like prebiotics; 
cedures [23] offer much promise over the conventional 
phenotypic approach, which is prone to error through 
metabolic plasticity of the organisms, operator subjec- 
tivity and the laborious nature of the analysis. In 
particular, probing technologies are attractive for use 
in large-scale volunteer trials, where effects on fecal 
microorganisms can be detected on stored samples. 
Conclusions 
The gastrointestinal microflora is an important element 
in the health of the host animal. Environmental factors, 
diet, medication and stress can all adversely affect the 
composition and/or activity of the gut flora. The 
deficiencies created can be repaired either by added 
viable organisms (probiotics) or by stimulating specific 
components (e.g. bifidobacteria) of the flora with 
chemical supplements (prebiotics). In these two differ- 
ent ways, the gut flora may be reconstituted to allow 
the host to derive maximum benefit from the associa- 
tion. It is clear that in the development of probiotics 
and prebiotics, the realistic health consequences must 
not be lost sight of. This article has suggested that 
promotion of resistance to gastrointestinal infections 
offers a great deal of promise. It  is important that well- 
conducted trials are carried out to exploit this simple 
method of consumer protection. 
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